Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Matthew Perrone

FDA expedites review of three psychedelic drugs after Trump order

  • The FDA has announced an "ultra-fast" review of three psychedelic drugs aimed at treating mental health conditions, including depression and PTSD.
  • President Donald Trump signed an executive order last weekend to accelerate access and ease restrictions on psychedelics, which are currently illegal under federal law.
  • The FDA awarded priority review vouchers for psilocybin, the active ingredient in magic mushrooms, for difficult-to-treat depression, and for methylone, related to MDMA, for post-traumatic stress disorder.
  • These moves reflect growing support for mind-altering substances among Trump's supporters, including combat veterans and the "Make America Healthy Again" movement led by Health Secretary Robert F. Kennedy Jr.
  • The FDA also authorized initial testing of a drug related to ibogaine for alcohol use disorder, with podcaster Joe Rogan reportedly influencing Trump's interest in the substance.

IN FULL

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.